Market News & Trends
Roivant Announces Positive IMVT-1402 Initial 600-mg MAD Results That Confirm Best-in-Class Potential
Immunovant, Inc. recently announced initial data from 600-mg MAD cohort of a Phase 1 clinical trial of IMVT-1402 in healthy adults. The results show that…
Evaxion to Unveil Potentially Groundbreaking AI-Immunology Precision Cancer Vaccine Concept
Evaxion Biotech A/S recently announced the presentation of its novel precision vaccine concept at the 65th American Society of Hematology (ASH) Annual Meeting, taking place…
Roivant & Priovant Announce Results From Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
Roivant and Priovant recently announced the Phase 2 study evaluating oral brepocitinib in adult patients with moderate to severe active lupus did not meet its…
GRI Bio Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis
GRI Bio, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application for GRI-0621 for the treatment of IPF. The…
ADvantage Therapeutics Commences Enrollment for Phase 2b Clinical Trial for Alzheimer’s Disease Treatment
ADvantage Therapeutics, Inc. recently announced the first patient enrolled in the company’s European Phase 2b clinical trial on its lead candidate AD04 for the treatment…
Alladapt Immunotherapeutics Receives FDA Fast Track Designation for the Treatment of Mono- and Multi-Food Allergies
Alladapt Immunotherapeutics, Inc. recently announced that ADP101, its investigational multi-food oral immunotherapy (mOIT) designed to simultaneously treat allergy to one or more of the world’s…
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion & Enrollment of First Patient Into Phase 3 Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
Aerovate Therapeutics, Inc. recently announced the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) Phase 2b/Phase 3 study evaluating AV-101,…
Symbiosis Pharmaceutical Services Granted MHRA License Following Significant Investment
Symbiosis Pharmaceutical Services has recently launched new in-house analytical and microbiological capabilities to enable testing of small molecule, biological, and Advanced Therapeutic Medicinal Products (ATMP)…
Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to EMA
Anavex Life Sciences Corp. recently announced representatives of Anavex met with team members of the European Medicines Agency (EMA). These meetings discussed the debilitating pathology…
Yamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79 to Treat the Core Symptoms of Autism Spectrum Disorder
Yamo Pharmaceuticals LLC recently announced it has completed enrollment in its Phase 2 study evaluating L1-79 in adolescents and young adults with autism spectrum disorder…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….